These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 37968277)

  • 1. PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors.
    Searcy MB; Larsen RK; Stevens BT; Zhang Y; Jin H; Drummond CJ; Langdon CG; Gadek KE; Vuong K; Reed KB; Garcia MR; Xu B; Kimbrough DW; Adkins GE; Djekidel N; Porter SN; Schreiner PA; Pruett-Miller SM; Abraham BJ; Rehg JE; Hatley ME
    Nat Commun; 2023 Nov; 14(1):7291. PubMed ID: 37968277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Ahn EH; Mercado GE; Laé M; Ladanyi M
    Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
    Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
    Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
    Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG
    J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
    Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV
    Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma.
    Kim YY; Gryder BE; Sinniah R; Peach ML; Shern JF; Abdelmaksoud A; Pomella S; Woldemichael GM; Stanton BZ; Milewski D; Barchi JJ; Schneekloth JS; Chari R; Kowalczyk JT; Shenoy SR; Evans JR; Song YK; Wang C; Wen X; Chou HC; Gangalapudi V; Esposito D; Jones J; Procter L; O'Neill M; Jenkins LM; Tarasova NI; Wei JS; McMahon JB; O'Keefe BR; Hawley RG; Khan J
    Nat Commun; 2024 Feb; 15(1):1703. PubMed ID: 38402212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative correlation of single-cell
    Regina C; Hamed E; Andrieux G; Angenendt S; Schneider M; Ku M; Follo M; Wachtel M; Ke E; Kikuchi K; Henssen AG; Schäfer BW; Boerries M; Wagers AJ; Keller C; Hettmer S
    Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34187933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma.
    Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J
    Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
    Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
    Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis.
    Oristian KM; Crose LES; Kuprasertkul N; Bentley RC; Lin YT; Williams N; Kirsch DG; Linardic CM
    Cancer Res; 2018 Oct; 78(19):5513-5520. PubMed ID: 30093562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
    Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
    Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PAX-FOXO1s trigger fast trans-differentiation of chick embryonic neural cells into alveolar rhabdomyosarcoma with tissue invasive properties limited by S phase entry inhibition.
    Gonzalez Curto G; Der Vartanian A; Frarma YE; Manceau L; Baldi L; Prisco S; Elarouci N; Causeret F; Korenkov D; Rigolet M; Aurade F; De Reynies A; Contremoulins V; Relaix F; Faklaris O; Briscoe J; Gilardi-Hebenstreit P; Ribes V
    PLoS Genet; 2020 Nov; 16(11):e1009164. PubMed ID: 33175861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
    Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
    Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BAF complexes drive proliferation and block myogenic differentiation in fusion-positive rhabdomyosarcoma.
    Laubscher D; Gryder BE; Sunkel BD; Andresson T; Wachtel M; Das S; Roschitzki B; Wolski W; Wu XS; Chou HC; Song YK; Wang C; Wei JS; Wang M; Wen X; Ngo QA; Marques JG; Vakoc CR; Schäfer BW; Stanton BZ; Khan J
    Nat Commun; 2021 Nov; 12(1):6924. PubMed ID: 34836971
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Kendall GC; Watson S; Xu L; LaVigne CA; Murchison W; Rakheja D; Skapek SX; Tirode F; Delattre O; Amatruda JF
    Elife; 2018 Jun; 7():. PubMed ID: 29869612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity.
    Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A
    Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
    Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
    Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pax3 loss of function delays tumour progression in kRAS-induced zebrafish rhabdomyosarcoma models.
    Kahsay A; Rodriguez-Marquez E; López-Pérez A; Hörnblad A; von Hofsten J
    Sci Rep; 2022 Oct; 12(1):17149. PubMed ID: 36229514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death.
    Ommer J; Selfe JL; Wachtel M; O'Brien EM; Laubscher D; Roemmele M; Kasper S; Delattre O; Surdez D; Petts G; Kelsey A; Shipley J; Schäfer BW
    Cancer Res; 2020 Feb; 80(4):832-842. PubMed ID: 31888889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target.
    Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG
    Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.